Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction

Zifeng Yang; Ruifeng Tian; Xiao-Jing Zhang; Jingjing Cai; Zhi-Gang She; Hongliang Li

doi:10.3389/fcvm.2022.1120085

Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction

Front Cardiovasc Med. 2023 Jan 12:9:1120085. doi: 10.3389/fcvm.2022.1120085. eCollection 2022.

Authors

Zifeng Yang^{1

2}, Ruifeng Tian^{1

2}, Xiao-Jing Zhang^{2

3}, Jingjing Cai⁴, Zhi-Gang She^{1

2}, Hongliang Li^{1

2

3

5}

Affiliations

¹ Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
² Institute of Model Animal, Wuhan University, Wuhan, China.
³ School of Basic Medical Sciences, Wuhan University, Wuhan, China.
⁴ Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, China.
⁵ Gannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, China.

Abstract

In the past few decades, non-alcoholic fatty liver disease (NAFLD) and heart failure with preserved ejection fraction (HFpEF) have become the most common chronic liver disease and the main form of heart failure (HF), respectively. NAFLD is closely associated with HFpEF by sharing common risk factors and/or by boosting systemic inflammation, releasing other secretory factors, and having an expansion of epicardial adipose tissue (EAT). Therefore, the treatments of NAFLD may also affect the development and prognosis of HFpEF. However, no specific drugs for NAFLD have been approved by the Food and Drug Administration (FDA) and some non-specific treatments for NAFLD are applied in the clinic. Currently, the treatments of NAFLD can be divided into non-pharmacological and pharmacological treatments. Non-pharmacological treatments mainly include dietary intervention, weight loss by exercise, caloric restriction, and bariatric surgery. Pharmacological treatments mainly include administering statins, thiazolidinediones, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and metformin. This review will mainly focus on analyzing how these treatments may affect the development and prognosis of HFpEF.

Keywords: epicardial adipose tissue; heart failure with preserved ejection fraction; nonalcoholic fatty liver disease; risk factor; secretory factors; systemic inflammation; treatment.

Publication types

Review

Grants and funding

This work was supported by grants from the National Natural Science Foundation of China (82270390, 81970364, 82170595, 82170436, and 81970070) and the Hubei Province Innovation Platform Construction Project (20204201117303072238).